We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted loss per share of $2.56, which surpassed the Zacks Consensus Estimate by 12.03%. GRAIL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.52%.
Q3 Estimates for GRAL
The Zacks Consensus Estimate for revenues is pegged at $43.1 million, which suggests an increase of 19% from the year-ago reported figure.
The Zacks Consensus Estimate for loss per share is pinned at $2.78, indicating a year-over-year improvement of 13%. The estimate has moved north 6 cents in the past 60 days.
Here’s a quick overview of the company’s performance prior to the announcement.
Key Factors Likely to Have Driven GRAL’s Q3 Performance
In the third quarter, GRAIL is likely to have benefited from strong growth in Galleri test volumes, supported by increasing physician adoption, expanding digital health partnerships and growing clinical evidence.
Growing physician adoption for Galleri and higher prescribing activity, along with the addition of approximately 1,000 new ordering providers during the previous quarter, are likely to have boosted growth in the to-be-reported quarter.
Results from the PATHFINDER 2 and NHS-Galleri studies demonstrated the potential of Galleri to improve cancer detection when added to standard-of-care screening. The addition of Galleri increased cancer detection rates by approximately 4-6.5x across the two studies. Evidence of improved early-stage cancer detection and the potential to facilitate curative-intent treatment likely further encouraged physician adoption and prescribing activity.
GRAIL's digital health business must have further contributed to third-quarter growth through the expansion of new and existing partnerships. Electronic ordering integrations with Quest and Athena helped expand the prescriber base and encourage more frequent prescribing among existing physicians.
Strategic partnerships are likely to have supported Galleri adoption and international expansion during the third quarter. GRAIL’s collaboration with Priority Health enabled employer groups under certain plans to add Galleri to their existing screening coverage. Additionally, the $110 million strategic financing from Samsung, completed in June, enabled GRAIL to begin working with Samsung C&T Corporation on plans to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore.
During the previous quarter, non-GAAP adjusted gross profit was up 34% year over year, primarily driven by improved fixed cost leverage from higher volumes and a decrease in sample reprocessing costs. We expect this trend to have persisted in the to-be-reported quarter.
What Our Model Suggests for GRAL
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: GRAIL has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
Key Takeaways
GRAIL, Inc. (GRAL - Free Report) is scheduled to release third-quarter 2026 results on Nov. 4, after the closing bell.
In the last reported quarter, the company posted adjusted loss per share of $2.56, which surpassed the Zacks Consensus Estimate by 12.03%. GRAIL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.52%.
Q3 Estimates for GRAL
The Zacks Consensus Estimate for revenues is pegged at $43.1 million, which suggests an increase of 19% from the year-ago reported figure.
The Zacks Consensus Estimate for loss per share is pinned at $2.78, indicating a year-over-year improvement of 13%. The estimate has moved north 6 cents in the past 60 days.
Here’s a quick overview of the company’s performance prior to the announcement.
Key Factors Likely to Have Driven GRAL’s Q3 Performance
In the third quarter, GRAIL is likely to have benefited from strong growth in Galleri test volumes, supported by increasing physician adoption, expanding digital health partnerships and growing clinical evidence.
Growing physician adoption for Galleri and higher prescribing activity, along with the addition of approximately 1,000 new ordering providers during the previous quarter, are likely to have boosted growth in the to-be-reported quarter.
Results from the PATHFINDER 2 and NHS-Galleri studies demonstrated the potential of Galleri to improve cancer detection when added to standard-of-care screening. The addition of Galleri increased cancer detection rates by approximately 4-6.5x across the two studies. Evidence of improved early-stage cancer detection and the potential to facilitate curative-intent treatment likely further encouraged physician adoption and prescribing activity.
GRAIL's digital health business must have further contributed to third-quarter growth through the expansion of new and existing partnerships. Electronic ordering integrations with Quest and Athena helped expand the prescriber base and encourage more frequent prescribing among existing physicians.
GRAIL, Inc. Price and EPS Surprise
GRAIL, Inc. price-eps-surprise | GRAIL, Inc. Quote
Strategic partnerships are likely to have supported Galleri adoption and international expansion during the third quarter. GRAIL’s collaboration with Priority Health enabled employer groups under certain plans to add Galleri to their existing screening coverage. Additionally, the $110 million strategic financing from Samsung, completed in June, enabled GRAIL to begin working with Samsung C&T Corporation on plans to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore.
During the previous quarter, non-GAAP adjusted gross profit was up 34% year over year, primarily driven by improved fixed cost leverage from higher volumes and a decrease in sample reprocessing costs. We expect this trend to have persisted in the to-be-reported quarter.
What Our Model Suggests for GRAL
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below:
Earnings ESP: GRAIL has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks Rank #1 stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.